Neoplasia, 2023 Background: Immunotherapy plus tyrosine kinase inhibitor (IO-TKI) has become the first-line management for metastatic renal cell carcinoma (RCC), despite the absence of biomarkers.
Xianglai Xu, Jiajun Wang, Yanjun Zhu
exaly +4 more sources
Integrating virtual screening and molecular dynamics simulations to identify emodin as a PYCR1 inhibitor modulating docetaxel sensitivity in prostate cancer [PDF]
Journal of Enzyme Inhibition and Medicinal ChemistryDocetaxel (DTX) resistance is the main cause of treatment failure in castration-resistant prostate cancer (CRPC). Pyrroline-5-carboxylic acid reductase 1 (PYCR1) is an enzyme involved in proline metabolism.
Shuai Liu +12 more
doaj +3 more sources
Study on the effects and mechanisms of M2 macrophages on PYCR1-promoted biological behavior of hepatocellular carcinoma cells [PDF]
Scientific ReportsIn this study, we aimed to investigate the effects of PYCR1 and M2-type macrophages on the malignant behaviors of hepatocellular carcinoma (HCC) cells and determine the mechanisms underlying these effects.
Xinxin Jin +4 more
doaj +3 more sources
PYCR1 is associated with papillary renal cell carcinoma progression
Open Medicine (Poland), 2019 We aimed to determine the function of pyrroline-5-carboxylate reductase 1 (PYCR1) on progression of papillary renal cell carcinoma (PRCC) and related mechanism.
Ling Liu
exaly +4 more sources
Pro-tumorigenic activity of PYCR1 in gastric cancer through regulating the PI3K/AKT signaling
HeliyonBackground: The primary objective of this investigation was to assess the impact of pyrroline-5-carboxylate reductase 1 (PYCR1) on the progression of gastric cancer (GC), specifically focusing on tumor growth and metastatic potential.
Huijie Xiao +4 more
doaj +4 more sources
Multi-omics analyses related to mitochondria and ageing in triple-negative breast cancer implicate PYCR1 potentiates tumor progression [PDF]
Cancer Cell InternationalBackground Triple-negative breast cancer (TNBC), defined by the lack of expression of Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2), is associated with increased rates of recurrence and mortality.
Jia-nan Huang +4 more
doaj +3 more sources
BHLHE41 inhibits bladder cancer progression via regulation of PYCR1 stability and thus inactivating PI3K/AKT signaling pathway [PDF]
European Journal of Medical ResearchBackground The basic helix-loop-helix family member e41 (BHLHE41) is frequently dysregulated in tumors and plays a crucial role in malignant progression of various cancers.
Shuai Xiao +3 more
doaj +3 more sources
Confirming the enzymatic activity and neurodevelopmental trajectory of PYCR1 mutation in one child with autosomal-recessive cutis laxa type 2 [PDF]
Molecular Genetics and GenomicsAutosomal-recessive cutis laxa type 2 (ARCL2) is a rare genetic disorder caused by pyrroline-5-carboxylate reductase 1 (PYCR1) mutations and characterized by loose and sagging skin, typical facial features, intrauterine growth retardation, and ...
Shaofang Shangguan +2 more
exaly +3 more sources
Crosstalk between FTH1 and PYCR1 dysregulates proline metabolism and mediates cell growth in KRAS-mutant pancreatic cancer cells [PDF]
Experimental and Molecular MedicineFerritin, comprising heavy (FTH1) and light (FTL) chains, is the main iron storage protein, and pancreatic cancer patients exhibit elevated serum ferritin levels.
Ji Min Park +14 more
doaj +3 more sources
Nature Communications, 2023 The proline synthesis is importantly involved in tumor growth under hypoxia, while the underlying mechanism remains to be further investigated. Here we show that pyrroline-5-carpoxylate reductase-1 (PYCR1), displaying a constant nuclear localization, is ...
Ke Zheng +9 more
doaj +2 more sources